A combination of IV and IP administration of chemotherapy conveys a significant survival benefit among women with optimally debulked epithelial ovarian cancer, compared to IV administration alone. The three largest studies with the greatest survival advantage delivered cisplatin 100 mg/m2 IP. , the chemotherapy regimens mandated modification based on patient tolerance. The benefit appears to be approximately a 12-month improvement in median overall survival. It may also be associated with a significantly increased short-term risk of toxicity compared with IV chemotherapy; however, the toxicity is short-term and manageable.